

## Factors affecting mortality in geriatric patients hospitalized with COVID-19

Rabia BAĞ SOYTAŞ<sup>1,\*</sup>, Damla ÜNAL<sup>1</sup>, Pınar ARMAN<sup>1</sup>, Veysel SUZAN<sup>1</sup>, Tuğçe EMİROĞLU GEDİK<sup>1</sup>,  
Günay CAN<sup>2</sup>, Bora KORKMAZER<sup>3</sup>, Ridvan KARAALİ<sup>4</sup>, Şermin BÖREKÇİ<sup>5</sup>, Mert Ahmet KUŞKUCU<sup>6</sup>,  
Hakan YAVUZER<sup>1</sup>, Deniz SUNA ERDİNÇLER<sup>1</sup>, Alper DÖVENTAŞ<sup>1</sup>

<sup>1</sup>Division of Geriatrics, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey

<sup>2</sup>Department of Public Health, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey

<sup>3</sup>Department of Radiology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey

<sup>4</sup>Department of Infectious Diseases, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey

<sup>5</sup>Department of Pulmonary Diseases, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey

<sup>6</sup>Department of Medical Microbiology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Turkey

Received: 11.08.2020 • Accepted/Published Online: 12.12.2020 • Final Version: 30.04.2021

**Background/aim:** We aimed to investigate the factors affecting the mortality of patients aged 65 years or older who were hospitalized with the diagnosis of new coronavirus pneumonia (COVID-19).

**Materials and methods:** This is a retrospective study of patients 65 years old or older with COVID-19 who were hospitalized in İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital, between March 11 and May 28, 2020. Demographic, clinical, treatment, and laboratory data were extracted from electronic medical records. We used univariate and multivariate logistic regression methods to explore the risk factors for in-hospital death.

**Results:** A total of 218 patients (112 men, 106 women) were included, of whom 166 were discharged and 52 died in hospital. With univariate analysis, various clinical features and laboratory variables were found to be significantly different (i.e.  $P < 0.05$ ). In multivariate logistic regression analysis the following were independently associated with mortality: present malignancy [odds ratio (OR) = 4.817, 95% confidence interval (CI) = 1.107–20.958,  $P$ : 0.036]; dyspnea (OR = 4.652, 95% CI = 1.473–14.688,  $P$ : 0.009); neutrophil/lymphocyte ratio (NLR; OR = 1.097, 95% CI = 1.012–1.188,  $P$ : 0.025); the highest values of C-reactive protein (CRP; OR = 1.006, 95% CI = 1.000–1.012,  $P$ : 0.049), lactate dehydrogenase (LDH; OR = 1.002, 95% CI = 1.001–1.004,  $P$ : 0.003), and creatinine levels (OR = 1.497, 95% CI = 1.126–1.990,  $P$ : 0.006); oxygen saturation (SpO<sub>2</sub>) values on admission (OR = 0.897, 95% CI = 0.811–0.993,  $P$ : 0.036); and azithromycin use (OR = 0.239, 95% CI = 0.065–0.874,  $P$ : 0.031).

**Conclusion:** The presence of malignancy; symptoms of dyspnea; high NLR; highest CRP, LDH, and creatinine levels; and low SpO<sub>2</sub> on admission predicted mortality. On the other hand, azithromycin use was found to be protective against mortality. Knowing the causes predicting mortality will be important to treat future cases more successfully.

**Key words:** COVID-19, geriatrics, hospitalized patients, mortality, risk factors

### 1. Introduction

In December 2019, the pneumonia epidemic that was centered in the city of Wuhan, China, was defined as coronavirus disease 2019 (COVID-19) due to the newly defined severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) agent. This virus is thought to have been transmitted from a zoonotic infection, such as SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV) that is, transmitted from animals to humans. Coronaviruses are single chain, positive polarity, enveloped RNA viruses. Because of their positive polarity, they do not contain the RNA-dependent RNA polymerase enzyme;

however, they encode this enzyme in their genome. They have rod-like extensions on their surfaces [1]. The disease spectrum caused by a coronavirus in humans can range from simple colds to severe acute respiratory syndrome. It may cause clinical presentations in humans and animals with various degrees of respiratory, enteric, hepatic, nephrotic, and neurological involvements [2]. The World Health Organization (WHO) accepted COVID-19 as a global pandemic and declared an emergency on March 11, 2020.<sup>1</sup> That same day, the first case was reported <sup>1</sup>WHO (2021). WHO Timeline – COVID-19 [online]. Website <https://www.who.int/news-room/detail/08-04-2020-who-timeline---covid-19> [accessed 11 March 2020].

\* Correspondence: [drabiabag@gmail.com](mailto:drabiabag@gmail.com)

by Republic of Turkey Ministry of Health.<sup>2</sup> Although several predictions have been made about the end of the pandemic's progression and the occurrence of the second wave, much remains uncertain [3].

As is known, patients 65 years of age or over can be very frail due to their comorbidities and age-related physiological changes [4]. As a matter of fact, the data obtained from scientific studies have revealed that older adults are among the groups most at risk for the disease [5]. It causes higher mortality rates, especially in older people with other health problems, such as cardiovascular disease, chronic respiratory system disease, diabetes, or cancer [6]. Compared to people in a younger age group, the symptoms and course of the disease in older adults may also differ. Imperial College London's COVID-19 Response Team reports that those who show symptoms in their 70s are more than 20 times more likely to be hospitalized than those in their 20s [7]. In this study, we aimed to investigate the factors affecting the mortality and survival of older patients hospitalized with the diagnosis of COVID-19 in COVID inpatient clinics or the intensive care unit. Furthermore, we aimed to ensure early precautions will be taken in a second wave.

## 2. Methods

### 2.1. Participants

The participants were identified from inpatients of the İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital, by searching the hospital's electronic medical records between March 11 and May 28, 2020. Beginning March 11, the facility was changed to a pandemic hospital. Patients aged 65 years or older who were diagnosed with COVID-19 and discharged or died in hospital by May 28, 2020, were enrolled in this study. The diagnoses of all included patients were confirmed using the Diagnosis and Treatment Guideline for COVID-19 published by Republic of Turkey Ministry of Health.<sup>2</sup>

### 2.2. Data collection

Demographic data, application complaints, comorbidity, medication use, and smoking history were extracted from electronic medical records and retrospectively reviewed and analyzed. CURB-65 scores were calculated on admission. The abbreviation stands for the following, with one point assigned for a "yes": confusion, Urea > 41 mg/dL, respiratory rate > 30 breaths/min, blood pressure < 90/60 mm/Hg, and age ≥ 65. Complete blood count, neutrophil/lymphocyte ratio (NLR), C-reactive protein (CRP), procalcitonin, ferritin, lactate dehydrogenase (LDH), urea, creatinine, liver function tests, albumin, international

<sup>2</sup> Republic of Turkey Ministry of Health (2021). COVID-19 Information Page [online]. Website [https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19\\_Rehberi.pdf](https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf) [accessed 11 March 2020].

normalized ratio (INR), fibrinogen, and D-dimer levels were recorded on admission, as were the highest values of CRP, creatinine, D-dimer, LDH, and ferritin levels. The number of hospitalized days at intensive care units and inpatient clinics, number of days intubated, electrocardiogram (ECG) changes, presence of delirium, presence of pressure ulcers during hospitalization, oxygen treatment types, and oxygen saturation (SpO<sub>2</sub>) values on admission were noted from the clinical course of the patient files. Also recorded were COVID-19 polymerase chain reaction (PCR) test results, thorax computed tomography (CT) findings, used medicine for the treatment of COVID-19, and adverse effects and complications. Thorax CT findings were staged by a radiology specialist in accordance with the reporting recommendations of the Radiological Society of North America Expert Consensus. According to the findings in the images, they were classified as typical, indeterminate, atypical, or negative in appearance [8]. Patients with a typical, indeterminate, or atypical appearance were accepted as thorax CT positive and received COVID treatment. The mortality and discharge rates were examined. Patients who had no fever for the last three days, whose clinical findings and laboratory values decreased, and who had been hospitalized for at least seven days were discharged.

### 2.3. Statistical analysis

Data were expressed as medians (interquartile range) for continuous variables and counts and frequencies [number (percentage)] for categorical variables. A comparison of categorical variables between the discharged and deceased groups was performed using Pearson's  $\chi^2$  test with continuity correction or Fisher's exact test, where appropriate. The Mann-Whitney U test was used to compare differences in continuous variables between the two groups because they were all nonnormally distributed. Multivariable logistic regression modeling was used to explore independent risk factors for death. Regression analysis was performed for parameters associated with mortality within their own groups (comorbidities, symptoms, etc.). Multivariate regression analysis was also performed for the parameters that were significant in these analyses. Although some parameters, which were not associated with mortality in our study, related to mortality in the literature (age, hypertension) were also included in the multivariate regression analysis. Continuous variables were treated as continuous measures in the model. Statistical analyses were performed using SPSS version 21.0 (IBM Corporation, Armonk, NY, USA). Differences were considered to be statistically significant when two-sided P values were less than 0.05.

## 3. Results

The first cases in Turkey were reported on March 11. By May 28, the total number of cases had reached 160,979,

and the total number of deaths reported was 4461.<sup>3</sup> Between the same dates, 1808 cases and 86 deaths related to COVID-19 were reported at İstanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital, a pandemic hospital. Of the patients, 908 were hospitalized in the COVID inpatient clinics or intensive care unit, and 251 of the inpatients were over 65 years of age. Thirty-three of these 251 geriatric patients were excluded from the study because COVID PCR or thorax CT tests could not confirm the diagnoses despite clinical findings. The other 218 patients (112 men, 106 women) were included. Sixty-eight of the patients were hospitalized in the intensive care unit and 150 in the inpatient clinics. Among them, 52 died (34 men, 18 women) specifically, 70.5% (n: 48) of the patients who were hospitalized in the intensive care unit and 2.6% (n: 4) in the inpatient clinics. Mortality was 9.5% among all COVID-19 patients (n: 86) in the inpatient clinics or intensive care unit, regardless of age, while in the geriatric group, this rate increased to 23.9%. The patients were divided into three age groups ranging from 65–74 (n: 107), 75–84 (n: 86), and 85 or more (n: 25) years. Furthermore, this study investigated sex differences by placing participants into two groups: female and male. However, no significant difference was found between the sex and age groups in terms of mortality.

As shown in Table 1, the most common comorbidities were hypertension (66.0%), type 2 diabetes mellitus (31.7%), coronary artery disease (CAD; 31.2%), chronic obstructive pulmonary disease (COPD; 19.3%), congestive heart failure (CHF; 17.0%), and malignancy (14.7%). Of the patients, 18.8% were using an angiotensin-converting enzyme inhibitor (ACEI), and 25.7% were using an angiotensin receptor blocker (ARB). Polypharmacy was present in 49.5% of the patients, and no significant difference was found between age or sex groups. Also, 24.0% of patients had a fever, 39.0% had a cough, and 41.0% had shortness of breath. Other symptoms were less common (Table 1).

The patients' laboratory values on admission and the highest values are shown in Table 2. The COVID PCR tests were positive in 46.7% of the patients, and COVID findings were positive in thorax CTs in 91.3% of the patients. For 83 patients (38.0%), both their COVID PCR and thorax CT tests were positive. In 19 patients (8.7%), COVID PCR was positive while thorax CT was negative, and in 116 patients (53.2%), COVID PCR was negative while thorax CT was positive. The blood pressure of 5.0% of the patients was greater than 90/60 mmHg on admission.

The oxygen treatment types applied to patients during hospitalization are shown in Table 3. During

hospitalization, ECG changes were observed in 18.3%, delirium in 12.4%, and pressure ulcers in 3.2% of the patients. For COVID-19 treatment, 100% of patients used hydroxychloroquine, 78.0% azithromycin, 70.6% oseltamivir, 58.3% favipiravir, 7.3% lopinavir/ritonavir, 12.4% tocilizumab, 7.8% corticosteroid, and 78.4% anticoagulants. Adverse drug reactions occurred in 8.7% of the patients, and the majority of these adverse effects were prolonged QT on ECG (6.9%).

Thus far, this results section has profiled this study's 218 geriatric patients. Now, the focus shifts to the relationships between mortality and the patients' characteristics. The mortality rate of men was higher than that of women (P: 0.021). However, no significant relationship was found between age groups and death. In terms of comorbidities, although our study found no such relationship, some epidemiological studies have shown that hypertension is associated with increased mortality and morbidity in COVID-19 patients. On the other hand, our study did find CHF, malignancy, and dementia to be more common in patients who died (respectively, P: 0.035, < 0.001, and 0.03). Polypharmacy was found in 49.5% of the patients and was significantly higher in the patients who died (P: 0.021).

There was no relationship between the excess number of symptoms and death. When the symptoms were evaluated one by one, a significant relationship was found between cough and death and between dyspnea and death (respectively, P: 0.001 and < 0.001).

This study also investigated possible relationships between mortality and laboratory values. If the patient's levels of lymphocytes were lower and the white blood cell count and NLR were higher on admission, these changes in values were significantly related to mortality (respectively, P: 0.001, 0.002, and < 0.001). CRP, ferritin, and LDH on admission were all associated with mortality (respectively, P: < 0.001, 0.001, and < 0.001), as were their highest values (respectively, P: < 0.001, 0.001, and < 0.001). The highest value of D-dimer was also associated with mortality (P: < 0.001). In patients who died, INR, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) values on admission were significantly higher, and albumin values were lower. Urea and creatinine levels on admission and the highest creatinine values were higher in the patients who died (respectively, P: < 0.001, 0.04, and < 0.001).

CURB-65 is a severity score containing five variables used to determine the severity of community-acquired pneumonia [9]. In this study, mortality was significantly higher in patients with a CURB-65 score of four to five than in other groups (P: < 0.001). It was observed that patients with lower baseline SpO<sub>2</sub> values (P: < 0.001) and whose CURB-65 scores were four to five died more

<sup>3</sup> Republic of Turkey Ministry of Health (2021). COVID-19 Information Page [online]. Website [https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19\\_Rehberi.pdf](https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf) [accessed 28 March 2020].

**Table 1.** Demographics and clinical presentation in patients with COVID-19 pneumonia.

Characteristics	All patients	Recovery and discharge	Death	P value
n	218	166 (76.1 %)	52 (23.9 %)	
Age, Mean (25–75)	75.3 (70–81)	75 (69–81)	74.5 (70–80)	0.421
Age, groups, n (%)				
65–74	107 (49.1 %)	81 (48.8 %)	26 (50 %)	0.243
75–84	86 (39.4 %)	69 (41.6 %)	17 (32.7 %)	
≥85	25 (11.5 %)	16 (9.6 %)	9 (17.3 %)	
Sex				
Male n (%)	112 (51.4 %)	78 (47 %)	34 (65.4 %)	<b>0.021</b>
Female n (%)	106 (48.6 %)	88 (53 %)	18 (34.6 %)	
Comorbidity n (%)				
Hypertension	145 (66.5 %)	113 (68.1 %)	32 (61.5 %)	0.403
Diabetes	69 (31.7 %)	57 (34.3 %)	12 (23.1 %)	0.128
CAD	68 (31.2 %)	49 (29.5 %)	19 (36.5 %)	0.340
CHF	37 (17 %)	23 (13.9 %)	14 (26.9 %)	<b>0.035</b>
Malignancy	32 (14.7 %)	14 (8.4 %)	18 (34.6 %)	<b>&lt;0.001</b>
COPD	42 (19.3 %)	28 (16.9 %)	14 (26.9 %)	0.109
Chronic renal disease	28 (12.8 %)	19 (11.4 %)	9 (17.3 %)	0.270
Dementia	24 (11 %)	14 (8.4 %)	10 (19.2 %)	<b>0.03</b>
Cerebrovascular disease	19 (8.7 %)	13 (7.8 %)	6 (11.5 %)	0.406
Polypharmacy	108 (49.5 %)	75 (45.2 %)	33 (63.5 %)	<b>0.021</b>
ACEI n (%)	41 (18.8 %)	29 (17.5 %)	12 (23.1 %)	0.367
ARB n (%)	56 (25.7 %)	48 (28.9 %)	8 (15.4 %)	0.051
Smoking	44 (20.2 %)	30 (18.1 %)	14 (26.9 %)	0.165
Presence of symptoms, n (%)	207 (95 %)	156 (94 %)	51 (98.1 %)	0.238
Fever	53 (24.3 %)	41 (24.7 %)	12 (23.1 %)	0.812
Cough	85 (39 %)	75 (45.2 %)	10 (19.2 %)	<b>0.001</b>
Dyspnea	90 (41.3 %)	55 (33.1 %)	35 (67.3 %)	<b>&lt;0.001</b>
Fatigue	28 (12.8 %)	23 (13.9 %)	5 (9.6 %)	0.425
Known contact history	17 (7.8 %)	15 (9 %)	2 (3.8 %)	0.373
Nausea/vomiting	10 (4.6 %)	8 (4.8 %)	2 (3.8 %)	0.770
Loss of consciousness	10 (4.6 %)	6 (3.6 %)	4 (7.7 %)	0.255
Sore throat	9 (4.1 %)	9 (5.4 %)	0	0.119
Myalgia	8 (3.7 %)	8 (4.8 %)	0	0.107
Diarrhea	6 (2.8 %)	4 (2.4 %)	2 (3.8 %)	0.581
Chills	6 (2.8 %)	5 (3 %)	1 (1.9 %)	0.675
Headache	1 (0.5 %)	1 (0.6 %)	0	0.575

CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

( $P < 0.001$ ). COVID PCR and thorax CT positivity were not associated with mortality.

As predicted, it was found that patients died more if they had a high number of days of hospitalization and

intubation in the intensive care unit and used noninvasive and invasive mechanical ventilators. However, no relationship was found between the total number of hospitalization days and mortality. The use of a mask with

**Table 2.** Laboratory findings in patients with COVID-19 pneumonia.

Laboratory results, mean (25–75)	All patients	Recovery and discharge	Death	P value
Hemoglobin, g/dL	11.9 (10.6–13.1)	12.2 (10.6–13.3)	11.3 (10.3–12.2)	0.073
WBC, 10 <sup>3</sup> /μL	7.45 (5.3–10.7)	6.9 (5–8.8)	10.5 (7.4–13.5)	<b>0.001</b>
Platelets, 10 <sup>3</sup> /μL	211000 (160550–263550)	217000 (160900–263100)	196800 (148725–277500)	0.191
Lymphocyte, 10 <sup>3</sup> /μL	1.2 (0.8–1.7)	1.3 (0.9–1.9)	0.9 (0.5–1.3)	<b>0.002</b>
NLR, 10 <sup>3</sup> /μL	4.15 (2.27–8.78)	3.3 (1.8–5.2)	10.7 (5–18.2)	<b>&lt;0.001</b>
Ferritin, ng/mL	279.9 (102–685.7)	231 (91.7–582)	532 (282–1459)	<b>0.001</b>
Highest ferritin, ng/mL	516.6 (189.6–1264)	354.3 (165.8–822.5)	1543 (690–2000)	<b>0.001</b>
D-dimer, mg/L	1.45 (0.69–3.8)	1.17 (0.5–3.05)	3.4 (1.3–7.8)	0.052
Highest D-dimer, mg/L	3.97 (1.48–12.07)	2.69 (1.14–7.21)	11.9 (6.4–34.3)	<b>&lt;0.001</b>
Procalcitonin, ng/mL	0.13 (0.06–0.43)	0.09 (0.04–0.26)	0.55 (0.23–1.76)	0.260
LDH, IU/L	279.5 (210–405)	249 (201–352)	419 (293–638)	<b>&lt;0.001</b>
Highest LDH, IU/L	432 (304–697.7)	405 (269.7–559.2)	726 (488–1185)	<b>&lt;0.001</b>
CRP, mg/L	53 (21.7–120)	36 (147–947)	132 (53–177)	<b>&lt;0.001</b>
Highest CRP, mg/L	120.1 (42.7–231.9)	82.14 (33.01–162.6)	260 (210–325)	<b>&lt;0.001</b>
INR	1.1 (1.03–1.2)	1.1 (1.01–1.2)	1.2 (1.1–1.4)	<b>0.013</b>
Urea, mg/L	90 (86–94)	9 (7–14.2)	12 (5.2–18)	<b>&lt;0.001</b>
Creatinin, mg/L	1.02 (0.8–1.4)	1 (0.78–1.26)	1.24 (0.8–1.97)	<b>0.04</b>
Highest creatinin, mg/L	1.33 (0.95–2.02)	1.19 (0.91–1.61)	1.24 (0.8–1.97)	<b>&lt;0.001</b>
AST, IU/L	29.5 (19–45)	25.8 (18–38)	45 (30–57)	<b>0.004</b>
ALT, IU/L	17 (12–32)	16 (12–28)	23 (12.5–56.5)	<b>0.038</b>
Fibrinogen, mg/dL	456 (357–573)	451 (346–557)	499 (395–582)	0.088
Albumin, gr/dL	3.64 (3.2–4)	3.75 (3.3–4.05)	3.18 (2.84–3.79)	<b>&lt;0.001</b>

WBC, white blood cell; NLR, neutrophil/lymphocyte ratio; LDH, lactate dehydrogenase; CRP, C-reactive protein; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

a reservoir was associated with mortality ( $P < 0.001$ ).

It was found that patients who used azithromycin, one of the drugs used for COVID-19 treatment, died less ( $P: 0.009$ ). In contrast, the use of favipiravir was found to be higher in the patients who died ( $P < 0.001$ ).

In multivariate logistic regression analysis to detect the factors predicting mortality among older patients with COVID-19, malignancy; dyspnea; NLR; the highest values of CRP, creatinine, and LDH; azithromycin use; and SpO<sub>2</sub> values on admission were independently associated with mortality (Table 4).

#### 4. Discussion

This study investigated factors affecting mortality in hospitalized older adult patients with COVID-19. Many studies have shown that mortality increases with increasing age [10]. In a study with 72,314 cases, the overall mortality rate was 2.3%, but it was 8% in patients 70–79 years old and 14.5% in patients  $\geq 80$  years old [11]. In another

analysis by the Korean Centers for Disease Control and Prevention, the overall case fatality rate (CFR) in 11,344 patients with confirmed cases on May 28, 2020, was 2.4%; however, it was much higher in older adults (10.9% in patients 70–79 years and 26.6% in patients  $\geq 80$  years).<sup>4</sup> In a report published by the Italian Institute of Higher Health, the total CFR on March 26, 2020, was four times higher than in Korea or China (9.2%); however, the increase in mortality with age was similar to that in Korea and China. CFR was less than 1% in the 50–69 age group, 16.9% in the 70–79 age group, and 24.4% in the 80 and older age group.<sup>5</sup> In our study, no significant difference was found between mortality and age groups. This may be due to the fact that the number of patients in the 85 years and older age group is lower than the other groups. Also, another reason may be that comorbidities are independent of age.

The COVID-19 mortality rate was higher in male patients than female patients in this study ( $P: 0.021$ ). This finding contradicts another study concerning geriatric

**Table 3.** Clinical findings and treatment modalities in patients with COVID-19 pneumonia.

Clinical findings and treatment modalities	All patients	Recovery and discharge	Death	P value
Hospitalized days numbers in intensive care unit	10.09 (4–14)	8 (3.25–11.7)	10 (4–16.75)	<0.001
Intubated days numbers	9.05 (2.75–13.25)	5.5 (1.75–8)	8.5 (3–14)	<0.001
Total hospitalized days numbers	10 (7–15.25)	9 (7–14.25)	12 (5.25–18)	0.326
SpO <sub>2</sub> % on admission	94 (89–97)	95 (91–97)	88 (77–94)	<0.001
Blood pressure on admission, n (%)				
≤ 90/60	14 (6.4 %)	11 (6.6 %)	3 (5.7 %)	0.493
<90/60	204 (93.6)	155 (93.4 %)	49 (94.3 %)	
CURB65, n (%)				
1–2	156 (71.6%)	135 (81.3 %)	21 (40.4 %)	<0.001
3	41 (18.8 %)	25 (15.1 %)	16 (30.8 %)	
4–5	21 (9.6 %)	6 (3.6 %)	15 (28.8 %)	
COVID PCR positive, n (%)	102 (46.7 %)	75 (45 %)	27 (51.9 %)	0.561
Thorax CT positive, n (%)	199 (91.3 %)	151 (91 %)	48 (92.3 %)	0.06
Thorax CT Classification, n (%)				
0 (negative)	19 (8.7 %)	15 (9 %)	4 (7.6 %)	0.094
1 (atypical)	24 (11 %)	14 (8.4 %)	10 (19.2 %)	
2 (indeterminate)	40 (18.3 %)	30 (18.1 %)	10 (19.2 %)	
3 (typical)	135 (61.9 %)	107 (64.5 %)	28 (53.8 %)	
Oxygen treatment, n (%)				
Nasal	126 (57.8 %)	98 (59 %)	28 (46.2 %)	0.508
Mask with a reservoir	26 (11.9 %)	7 (4.2 %)	19 (36.5 %)	<0.001
High Flow	15 (6.9 %)	9 (5.4 %)	6 (11.5 %)	0.204
NIMV	24 (11 %)	8 (4.8 %)	16 (30.8 %)	<0.001
IMV	57 (26.1 %)	10 (6 %)	47 (90.4 %)	<0.001
Delirium	27 (12.4 %)	19 (11.5 %)	8 (15.7 %)	0.431
Pressure ulcer	7 (3.2 %)	5 (3 %)	2 (3.8 %)	0.766
ECG change	40 (18.3 %)	28 (16.9 %)	12 (23.1 %)	0.313
COVID treatment, n (%)				
Hydroxychloroquine	215 (98.6 %)	166 (100 %)	52 (100 %)	0.425
Azithromycin	170 (78%)	136 (82.4 %)	34 (65.4 %)	0.009
Oseltamivir	154 (70.6 %)	117 (71.3 %)	37 (71.2 %)	0.979
Favipiravir	127 (58.3 %)	80 (48.5 %)	47 (90.4 %)	<0.001
Lopinavir/ritonavir	16 (7.3 %)	13 (7.8 %)	3 (5.8 %)	0.619
Tocilizumab	27 (12.4 %)	22 (13.3 %)	5 (9.6 %)	0.479
Anticoagulants	171 (78.4 %)	132 (79.5 %)	39 (75 %)	0.635
Corticosteroids	17 (7.8 %)	10 (6 %)	7 (13.5 %)	0.081

SpO<sub>2</sub>, oxygen saturation; COVID PCR, new coronavirus pneumonia polymerase chain reaction; CT, computerized tomography; NIMV, noninvasive mechanical ventilation; IMV, invasive mechanical ventilation; ECG, electrocardiography.

patients and the factors affecting mortality, which found no significant relationship between sex and death [12]. Furthermore, our study's multivariate regression analysis did not point to sex as a factor that predicts mortality.

However, in a large-scale study involving 1663 patients, mortality was higher in men than in women, as in our study [13]. In addition, previous studies have reported that men are more affected by SARS and MERS infections.

**Table 4.** Logistic regression analysis of COVID-19 mortality risk factors.

Variable	Univariate analysis		Multivariate analyses	
	OR (95% CI)	P value	OR (95% CI)	P value
Age, year	1.018 (0.976–1.062)	0.410	0.991 (0.913–1.075)	0.819
Sex	0.469 (0.246–0.897)	<b>0.022</b>	0.614 (0.186–2.022)	0.423
Hypertension	0.750 (0.393–1.433)	0.384	0.317 (0.79–1.274)	0.106
Malignancy	5.748(2.605–12.681)	<b>&lt;0.001</b>	4.817(1.107–20.958)	<b>0.036</b>
Dementia	2.585 (1.072–6.235)	<b>0.035</b>	3.252(0.673–15.711)	0.142
Dsypnea	4.155 (2.140–8.067)	<b>&lt;0.001</b>	4.652(1.473–14.688)	<b>0.009</b>
Polypharmacy	2.107 (1.109–4.004)	<b>0.023</b>	1.741 (0.475–6.384)	0.403
NLR, 10 <sup>3</sup> /μL	1.192 (1.122–1.267)	<b>&lt;0.001</b>	1.097 (1.012–1.188)	<b>0.025</b>
Highest D-dimer, mg/L	1.049 (1.026–1.072)	<b>&lt;0.001</b>	1.001 (0.961–1.042)	0.968
Highest CRP, mg/L	1.014 (1.01–1.018)	<b>&lt;0.001</b>	1.006 (1.000–1.012)	<b>0.049</b>
Highest LDH, IU/L	1.003 (1.002–1.005)	<b>&lt;0.001</b>	1.002 (1.001–1.004)	<b>0.003</b>
Highest creatinin, mg/L	1.627 (1.283–2.063)	<b>&lt;0.001</b>	1.497 (1.126–1.990)	<b>0.006</b>
SpO <sub>2</sub> % on admission	0.850 (0.799–0.903)	<b>&lt;0.001</b>	0.897 (0.811–0.993)	<b>0.036</b>
Azithromycin	0.403 (0.200–0.809)	<b>0.011</b>	0.239 (0.065–0.874)	<b>0.031</b>

One of the reasons for this situation may be that women have different immune responses due to sex or pay more attention to leading a healthy life. Another reason may be that malignancy was detected more frequently in males in our patient group (P: 0.033), and malignancy was associated with mortality.

Among the comorbidities, malignancy was significantly associated with mortality (OR = 4.817, 95% CI = 1.107–20.958, P: 0.036), which was consistent with other studies' findings. A study comparing COVID-19 patients with and without cancer history found that malignancy was an independent risk factor for mortality, similar to our study [14]. This result may be due to the different immune and inflammatory responses of patients with a history of cancer.

The angiotensin-converting enzyme 2 (ACE2) has been shown to be a coreceptor for viral entry of SARS-CoV-2, suggesting that it has a role in the pathogenesis of COVID-19 [15]. Therefore, ACEI and ARB use are thought to increase COVID-19 mortality and morbidity. However, some studies have shown that ACEIs prescribed at the clinic do not inhibit ACE2, which acts as a carboxypeptidase [16]. Similarly, in our study, no relationship was found between ACEI and ARB use and mortality.

In a study comparing patients infected with COVID-19 with and without dementia, dementia was significantly associated with mortality [17]. Although regression analysis did not predict mortality in our study, it was observed that dementia was significantly higher in

patients who died. Since it is difficult to identify symptoms of atypical COVID-19 in dementia patients, the interval between the onset of symptoms and hospital admission may have been prolonged, which may have adversely affected the prognosis.

There is no clear consensus for polypharmacy, and there are different definitions. Some of these definitions are the use of two or more drugs within 240 days, using four or more drugs, or using five or more drugs [18]. Since the use of five or more drugs is a more accepted definition, we defined polypharmacy as the use of five or more drugs in our study. There is no research in the literature investigating the effect of polypharmacy on COVID-19 prognosis. In our study, while polypharmacy was found to be significantly high in patients who died, it was not one of the parameters predicting mortality in multivariate regression analysis.

Symptoms were present in 95.0% of the patients, but there was no relationship between the presence of symptoms and mortality. Since almost all the patients had symptoms, we can say that there was no significant relationship between mortality and whether there were symptoms. Although fever is the most common symptom in the general population (98.0%) [19], the most common symptom in our study was dyspnea (41.0%). Due to decreased immune system response in older adults, fever response to infections is also generally reduced. In our study, 24.0% of patients had a fever, which is a much lower percentage than the overall COVID-19 patients.

Among the symptoms, a significant relationship was only found between dyspnea and mortality (OR = 4.652, 95% CI = 1.473–14.688, P: 0.009). Dyspnea in those who died was twice as frequent as in those who were discharged. This result may indicate that a COVID-19 patient presenting with dyspnea will have a worse course of infection than another patient without dyspnea.

There are studies in the literature about the laboratory predictors of death from COVID-19. In our study's multivariate regression analysis, it was determined that NLR and the highest values of CRP, creatinine, LDH levels may predict mortality. NLR is a marker of systemic inflammation predicting prognosis in various pathological conditions [20]. Recently, in community-acquired pneumonia, NLR has been found to have more prognostic power than known infection markers, such as CRP, white blood cell count, and neutrophil count [21]. There are also studies showing that the lymphocyte count affects the prognosis of COVID-19 disease [22]. Research has reported that severe COVID-19 cases had a higher neutrophil count and lower lymphocyte count than nonsevere patients, so NLR tends to be higher in patients with severe infection [23]. In addition to these studies, our study found NLR to be one of the predictors of mortality in COVID-19 patients (OR = 1.097, 95% CI = 1.012–1.188, P: 0.025). NLR may be a parameter that can be easily used to predict mortality since it can be calculated with a simple hemogram test. Some studies have reported that an elevated CRP is related to COVID-19 mortality [24]. In this study, the highest CRP values were associated with mortality (OR = 1.006, 95% CI = 1.000–1.012, P: 0.049). A cytokine storm occurs during virus invasion and can interact with excessive neutrophil infiltration, leading to the formation of harmful inflammatory processes. The immune system is suppressed, and the T lymphocyte response decreases. As a result, accompanying bacterial infections occur. These conditions may be the reason why elevated CRP and NLR predict mortality.

Similar to some studies, in this study, the relationship between high D-dimer values and mortality was determined [25]. Research has shown that the risk of both arterial and venous thromboembolism increases, especially in patients with a severe course of COVID-19 [26]. This may be the reason why a high D-dimer level is found to be associated with mortality. In response, anticoagulants have been included in the COVID-19 treatment protocols. Higher LDH values are not surprising in COVID-19 patients who died (OR = 1.002, 95% CI = 1.001–1.004, P: 0.003). There is reliable evidence that increased LDH values reflect the degree of pulmonary damage in patients with acute respiratory distress syndrome. Also, these data have been reported with SARS [27]. It was reported that multiorgan failure may be seen in severe COVID-19

cases [28]. The fact that the highest creatinine values in our study were associated with mortality may actually be a result of serious disease (OR = 1.497, 95% CI = 1.126–1.990, P: 0.006).

It is already known that hypoxemia is a sign of poor prognosis in pulmonary diseases, and the indicators for hypoxemia are used to evaluate the severity of COVID-19 [19]. Therefore, it is not surprising that the lower SpO<sub>2</sub> values on admission predicted mortality in our study (OR = 0.897, 95% CI = 0.811–0.993, P: 0.036). A mask with a reservoir is used in inpatient clinics to stave off transferring to intensive care unit those patients who worsen in the service follow-up and whose SpO<sub>2</sub> with nasal oxygen does not increase. In our study, there was a higher mortality rate in patients using a mask with reservoir (P: < 0.001). It may result from delaying the patient's timely arrival in intensive care, or from using the mask on patients whose clinic situations have already deteriorated.

In a study comparing patients who did not use any medication to patients who used azithromycin, hydroxychloroquine, or both azithromycin and hydroxychloroquine, using azithromycin alone or in combination with hydroxychloroquine did not affect mortality [29]. Another study found that mortality increased in those using only hydroxychloroquine compared to those using hydroxychloroquine and azithromycin [30]. Similarly, in our study, patients who used azithromycin died less, and azithromycin use had a protective effect on mortality in the multivariate logistic regression analysis (OR = 0.239, 95% CI = 0.065–0.874, P: 0.031). Azithromycin is effective against Zika and Ebola viruses in vitro [31,32]. It prevents serious respiratory infections when administered to patients with viral infections. It can be protective against mortality for both this reason and because it can prevent bacterial superinfections. Favipiravir use was found to be higher in patients who died (P: < 0.001). This may be due to the fact that favipiravir has been given to patients whose SpO<sub>2</sub> and clinical situation have deteriorated despite the classic triple treatment (hydroxychloroquine, azithromycin, and oseltamivir).

In this study, in which the factors affecting mortality in geriatric patients with COVID-19 were investigated, appropriate and contributing data were obtained from the literature. The limitations of our study were that the number of patients in the three age groups was dissimilar, and information about the time between a patient's onset of complaints and admission to the hospital was not available in the files. Our study needs to be supported by prospective studies, which will be done by evaluating frailty, an essential parameter in geriatric patients.

In conclusion, the COVID-19 outbreak has been

declared a global pandemic. The future course of COVID-19, when the first wave will end, and whether there will be a second wave are all important questions. The answers are not yet known. However, it is a known fact that COVID-19 is more serious and fatal in the older adults. Therefore, knowing the causes predicting mortality is important so that health care providers and others can be more conscious of them in future cases. Older patients with COVID-19 should be monitored more carefully, and more care should be taken in factors affecting mortality reported in our study and other studies in the literature.

#### Acknowledgment/disclaimers/conflict of interest

The authors thank all patients who participated in the study and all physicians in the relevant departments. We acknowledge all health-care workers involved in the diagnosis and treatment of patients in the world.

The authors have no conflicts of interest. There is no funding.

#### Contribution of authors

Concept and design: Alper Döventaş, Hakan Yavuzer,

Deniz Suna Erdinçler and Rabia Bağ Soytaş. Data collection: Damla Ünal, Pınar Arman, Veysel Suzan, Tuğçe Emiroğlu, Bora Korkmaz and Rabia Bağ Soytaş. Analysis and interpretation of data: Günay Can, Hakan Yavuzer, Alper Döventaş and Rabia Bağ Soytaş. Manuscript preparation: All authors.

#### Informed consent

This study was approved by the Ethical Review Committee of İstanbul University Cerrahpaşa, Cerrahpaşa Faculty of Medicine. Ethical Review Committee decision date and number: 05/06/2020-68153.

Informed consent was not obtained from the patients because the study was retrospective.

#### References

1. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. *Methods in Molecular Biology* 2015; 1282: 1-23. doi: 10.1007/978-1-4939-2438-7\_1
2. Su S, Wong G, Shi W, Liu J, Lai ACK et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. *Trends in Microbiology* 2016; 24 (6): 490-502. doi: 10.1016/j.tim.2016.03.003
3. Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. *International Journal of Biological Sciences* 2020; 16 (10): 1753-1766. doi: 10.7150/ijbs.45134
4. Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L et al. Physical frailty: ICFSR International Clinical Practice Guidelines for identification and management. *Journal of Nutrition, Health and Aging* 2019; 23 (9): 771-787. doi: 10.1007/s12603-019-1273-z
5. Landi F, Barillaro C, Bellieni A, Brandi V, Carfi A et al. The new challenge of geriatrics: saving frail older people from the SARS-COV-2 pandemic infection. *Journal of Nutrition, Health and Aging* 2020; 24 (5): 466-470. doi: 10.1007/s12603-020-1356-x
6. Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3
7. Eubank S, Eckstrand I, Lewis B, Venkatramanan S, Marathe M et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. *Bulletin of Mathematical Biology* 2020; 82 (4): 52. doi: 10.1007/s11538-020-00726-x
8. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH et al. Radiological Society of North America Expert consensus statement on reporting chest CT findings related to COVID-19: endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA - Secondary Publication. *Journal of Thoracic Imaging* 2020; 35 (4): 219-227. doi: 10.1097/RTI.0000000000000524
9. Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003; 58 (5): 377-82. doi: 10.1136/thorax.58.5.377
10. Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D et al. COVID-19 and older adults: what we know. *Journal of American Geriatric Society* 2020; 68 (5): 926-929. doi: 10.1111/jgs.16472
11. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Journal of the American Medical Association* 2020; 323 (13): 1239-1242. doi: 10.1001/jama.2020.2648

12. Sun H, Ning R, Tao Y, Yu C, Deng X et al. Risk factors for mortality in 244 older adults with COVID-19 in Wuhan, China: a retrospective study. *Journal of American Geriatric Society* 2020; 68 (6): E19-E23. doi: 10.1111/jgs.16533
13. Yu C, Lei Q, Li W, Wang X, Liu W et al. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: a retrospective study in Wuhan, China. *American Journal of Preventive Medicine* 2020; 59 (2): 168-175. doi: 10.1016/j.amepre.2020.05.002
14. Meng Y, Lu W, Guo E, Liu J, Yang B et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. *Journal of Hematology & Oncology* 2020; 13 (1): 75. doi: 10.1186/s13045-020-00907-0
15. Zhou P, Yang XL, Wang XG, Hu B, Zhang L et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579 (7798): 270-273. doi: 10.1038/s41586-020-2012-7
16. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. *Biochemical Journal* 2004; 383 (Pt 1): 45-51. doi: 10.1042/BJ20040634
17. Bianchetti A, Rozzini R, Guerini F, Boffelli S, Ranieri P et al. Clinical presentation of COVID19 in dementia patients. *Journal of Nutrition, Health and Aging* 2020; 24 (6): 560-562. doi: 10.1007/s12603-020-1389-1
18. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? a systematic review of definitions. *BMC Geriatrics* 2017; 17 (1): 230. doi: 10.1186/s12877-017-0621-2
19. Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5
20. Huang H, Wan X, Bai Y, Bian J, Xiong J et al. Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma. *Cancer Management and Research* 2019; 11: 5157-5162. doi: 10.2147/CMAR.S192532
21. Cataudella E, Giraffa CM, Di Marca S, Pulvirenti A, Alaimo S et al. Neutrophil-to-lymphocyte ratio: an emerging marker predicting prognosis in elderly adults with community-acquired pneumonia. *Journal of American Geriatric Society* 2017; 65 (8): 1796-1801. doi: 10.1111/jgs.14894
22. Liu Y, Du X, Chen J, Jin Y, Peng L et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *Journal of Infection* 2020; 81 (1): e6-e12. doi: 10.1016/j.jinf.2020.04.002
23. Qin C, Zhou L, Hu Z, Zhang S, Yang S et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clinical Infectious Diseases* 2020; 71 (15): 762-768. doi: 10.1093/cid/ciaa248
24. Wang K, Zuo P, Liu Y, Zhang M, Zhao X et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. *Clinical Infectious Diseases* 2020; ciaa538. doi: 10.1093/cid/ciaa538
25. Bousquet G, Falgarone G, Deutsch D, Derolez S, Lopez-Sublet M et al. ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19. *Aging (Albany NY)* 2020; 12 (12): 11306-11313. doi: 10.18632/aging.103583
26. Marietta M, Coluccio V, Luppi M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. *Internal and Emergency Medicine* 2020; 11: 1-13. doi: 10.1007/s11739-020-02432-x
27. Chiang CH, Shih JF, Su WJ, Perng RP. Eight-month prospective study of 14 patients with hospital-acquired severe acute respiratory syndrome. *Mayo Clinic Proceedings* 2004; 79 (11): 1372-1379. doi: 10.4065/79.11.1372
28. Huang D, Lian X, Song F, Ma H, Lian Z et al. Clinical features of severe patients infected with 2019 novel coronavirus: a systematic review and meta-analysis. *Annals of Translational Medicine* 2020; 8 (9): 576. doi: 10.21037/atm-20-2124
29. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. *Journal of the American Medical Association* 2020; 323 (24): 2493-2502. doi: 10.1001/jama.2020.8630
30. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *Med* 2020; 1 (1): 114-127. doi: 10.1016/j.medj.2020.06.001
31. Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. *Proceedings of the National Academy of Sciences of the United States of America* 2016; 113 (50): 14408-14413. doi: 10.1073/pnas.1618029113
32. Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN et al. Evaluation of Ebola virus inhibitors for drug repurposing. *ACS Infectious Diseases* 2015; 1 (7): 317-26. doi: 10.1021/acscinfedis.5b00030